Literature DB >> 11981137

Potential neuroprotective effects of acamprosate.

George F Koob1, Barbara J Mason, Philippe De Witte, John Littleton, George R Siggins.   

Abstract

This article represents the proceedings of a symposium at the 2001 RSA Meeting in Montreal, Canada. The organizers were Barbara J. Mason and George F. Koob. Anita M. Goodman served as chair. The presentations were (1) Acamprosate inhibits alcohol withdrawal-induced neurotoxicity in organotypic hippocampal cultures, by John Littleton; (2) Acamprosate alteration of NMDA receptor-dependent synaptic transmission and synaptic plasticity, by George R. Siggins; (3) Acamprosate and glutamate during ethanol withdrawal, by Philippe De Witte; (4) Clinical evidence of protective CNS effects of acamprosate in alcohol-dependent individuals, by Barbara J. Mason.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11981137

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN： 0145-6008            Impact factor:   3.455


  13 in total

Review 1.  Pharmacological strategies for detoxification.

Authors:  Alison M Diaper; Fergus D Law; Jan K Melichar
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

2.  Ontogenetic differences in ethanol's motivational properties during infancy.

Authors:  Michael E Nizhnikov; Ricardo Marcos Pautassi; Elena I Varlinskaya; Pouyan Rahmani; Norman E Spear
Journal:  Alcohol       Date:  2012-03-21       Impact factor: 2.405

Review 3.  The development of acamprosate as a treatment against alcohol relapse.

Authors:  Peter R Kufahl; Lucas R Watterson; M Foster Olive
Journal:  Expert Opin Drug Discov       Date:  2014-09-26       Impact factor: 6.098

4.  Glutamatergic transmission in the central nucleus of the amygdala is selectively altered in Marchigian Sardinian alcohol-preferring rats: Alcohol and CRF effects.

Authors:  Melissa A Herman; Florence P Varodayan; Christopher S Oleata; George Luu; Dean Kirson; Markus Heilig; Roberto Ciccocioppo; Marisa Roberto
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

Review 5.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 6.  Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.

Authors:  Barbara J Mason; Charles J Heyser
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

7.  Nociceptin/orphanin FQ decreases glutamate transmission and blocks ethanol-induced effects in the central amygdala of naive and ethanol-dependent rats.

Authors:  Marsida Kallupi; Florence P Varodayan; Christopher S Oleata; Diego Correia; George Luu; Marisa Roberto
Journal:  Neuropsychopharmacology       Date:  2013-10-30       Impact factor: 7.853

Review 8.  State-of-the-art behavioral and pharmacological treatments for alcohol use disorder.

Authors:  Lara A Ray; Spencer Bujarski; Erica Grodin; Emily Hartwell; ReJoyce Green; Alexandra Venegas; Aaron C Lim; Artha Gillis; Karen Miotto
Journal:  Am J Drug Alcohol Abuse       Date:  2018-10-29       Impact factor: 3.829

Review 9.  Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.

Authors:  Amanda J Abraham; Christina M Andrews; Samantha J Harris; Peter D Friedmann
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

10.  Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.

Authors:  H W Nam; V M Karpyak; D J Hinton; J R Geske; A M C Ho; M L Prieto; J M Biernacka; M A Frye; R M Weinshilboum; D-S Choi
Journal:  Transl Psychiatry       Date:  2015-08-18       Impact factor: 6.222
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.